证券之星消息,截至2023年10月24日收盘,友芝友生物-B(02496.HK)报收于8.92港元,下跌17.41%,换手率0.03%,成交量3.48万股,成交额34.38万港元。
资金流向数据方面,10月24日友芝友生物-B无主力资金净流入,无超大单资金净流入,无大单资金净流入,中单资金净流出13.77万港元,小单资金净流出9.86万港元。
投行对该股关注度不高,90天内无投行对其给出评级。
Wuhan YZY Biopharma Co Ltd is a China-based company principally engaged in the research, development, production and sales of pharmaceuticals. The Company is mainly engaged in the research, development and industrialization of bispecific antibody drugs. The Company's main products include anti-PD1&anti-CD3, anti-CD19&anti-CD3, and anti-CDX&CD3. The Company's drug products are mainly used in major diseases such as tumor, immunity, inflammation, cardiovascular and infection.
以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。证券之星力求但不保证该信息(包括但不限于文字、视频、音频、数据及图表)全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。